Cargando…
Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347527/ https://www.ncbi.nlm.nih.gov/pubmed/34362136 http://dx.doi.org/10.3390/jcm10153355 |
_version_ | 1783735111196344320 |
---|---|
author | Skroza, Nevena Bernardini, Nicoletta Tolino, Ersilia Proietti, Ilaria Mambrin, Alessandra Marchesiello, Anna Marraffa, Federica Rossi, Giovanni Volpe, Salvatore Potenza, Concetta |
author_facet | Skroza, Nevena Bernardini, Nicoletta Tolino, Ersilia Proietti, Ilaria Mambrin, Alessandra Marchesiello, Anna Marraffa, Federica Rossi, Giovanni Volpe, Salvatore Potenza, Concetta |
author_sort | Skroza, Nevena |
collection | PubMed |
description | Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate–severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate–severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate–severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2. |
format | Online Article Text |
id | pubmed-8347527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83475272021-08-08 Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience Skroza, Nevena Bernardini, Nicoletta Tolino, Ersilia Proietti, Ilaria Mambrin, Alessandra Marchesiello, Anna Marraffa, Federica Rossi, Giovanni Volpe, Salvatore Potenza, Concetta J Clin Med Article Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate–severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate–severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate–severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2. MDPI 2021-07-29 /pmc/articles/PMC8347527/ /pubmed/34362136 http://dx.doi.org/10.3390/jcm10153355 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Skroza, Nevena Bernardini, Nicoletta Tolino, Ersilia Proietti, Ilaria Mambrin, Alessandra Marchesiello, Anna Marraffa, Federica Rossi, Giovanni Volpe, Salvatore Potenza, Concetta Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title | Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title_full | Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title_fullStr | Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title_full_unstemmed | Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title_short | Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience |
title_sort | safety and impact of anti-covid-19 vaccines in psoriatic patients treated with biologics: a real life experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347527/ https://www.ncbi.nlm.nih.gov/pubmed/34362136 http://dx.doi.org/10.3390/jcm10153355 |
work_keys_str_mv | AT skrozanevena safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT bernardininicoletta safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT tolinoersilia safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT proiettiilaria safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT mambrinalessandra safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT marchesielloanna safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT marraffafederica safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT rossigiovanni safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT volpesalvatore safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience AT potenzaconcetta safetyandimpactofanticovid19vaccinesinpsoriaticpatientstreatedwithbiologicsareallifeexperience |